5-(aminomethyl)thiophene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-(aminomethyl)thiophene-2-carboxylic acid
• 英文别名: 5-(Azaniumylmethyl)thiophene-2-carboxylate
• 化学式: C₆H₇NO₂S
• 分子量: 157.193
• InChiKey: VHWSFLJKPUEMJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  91.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(aminomethyl)thiophene-2-carboxylic acid 在 盐酸 作用下， 以 水 为溶剂， 以100%的产率得到5-(Aminomethyl)thiophene-2-carboxylic acid hydrochloride
  参考文献：
  名称：

  Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase

  摘要：

  Two principal neurotransmitters are involved in the regulation of mammalian neuronal activity, namely, gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, and L-glutamic acid, an excitatory neurotransmitter. Low GABA levels in the brain have been implicated in epilepsy and several other neurological diseases. Because of GABA's poor ability to cross the blood-brain barrier (BBB), a successful strategy to raise brain GABA concentrations is the use of a compound that does cross the BBB and inhibits or inactivates GABA aminotransferase (GABA-AT), the enzyme responsible for GABA catabolism. Vigabatrin, a mechanism-based inactivator of GABA-AT, is currently a successful therapeutic for epilepsy, but has harmful side effects, leaving a need for improved GABA-AT inactivators. Here, we report the synthesis and evaluation of a series of heteroaromatic GABA analogues as substrates of GABA-AT, which will be used as the basis for the design of novel enzyme inactivators. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.08.009

文献信息

• Cyclic compounds linked by a heterocyclic ring useful as inhibitors of
  申请人：The DuPont Merck Pharmaceutical Company

  公开号：US05773411A1

  公开（公告）日：1998-06-30

  This invention relates to novel cyclic compounds linked by a heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation. A representative compound of the invention is cyclo-(D-Val-N(Me)Arg-Gly-Asp-\x9b5-aminomethyl!-2-furoate).

  本发明涉及通过杂环环系连接的新颖环状化合物，这些化合物作为血小板糖蛋白IIb/IIIa复合体的拮抗剂具有用途，涉及含有此类环状化合物的药物组合物，以及使用这些化合物抑制血小板聚集的方法。本发明的一个代表性化合物是环-(D-缬氨酸-N(甲基)精氨酸-甘氨酸-天冬氨酸-ε-氨基甲基-2-糠酸酯)。
• [EN] AMINOESTER DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINOESTERS
  申请人：CHIESI FARM SPA

  公开号：WO2016177849A1

  公开（公告）日：2016-11-10

  The invention relates to novel compounds which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

  这项发明涉及一种新型化合物，既是磷酸二酯酶4（PDE4）酶抑制剂，又是肌胆碱M3受体拮抗剂，以及制备这种化合物的方法、含有它们的组合物和它们的治疗用途。
• INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA
  申请人：Northwestern University

  公开号：US20180098952A1

  公开（公告）日：2018-04-12

  Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human γ-aminobutyric aminotransferase (GABA-AT).

  揭示了一种治疗具有选择性灭活裂殖孢子虫的鸟氨基转移酶的化合物、方法和组合物。具体来说，这些方法、化合物可用于治疗弓形虫和弓形虫病感染，以及治疗疟原虫和疟疾感染。本文披露的化合物被观察到相对于人类鸟氨基转移酶和人类γ-氨基丁酸氨基转移酶（GABA-AT）具有选择性地灭活弓形虫鸟氨基转移酶（TgOAT）。
• sGC STIMULATORS
  申请人：IRONWOOD PHARMACEUTICALS, INC.

  公开号：US20160031903A1

  公开（公告）日：2016-02-04

  Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

  本文描述了化学式I'和I的化合物，它们可用作sGC的刺激剂，特别是NO独立，血红素依赖性的刺激剂。这些化合物还可用于治疗、预防或管理本文中披露的各种疾病。
• sGC stimulators
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：US10183021B2

  公开（公告）日：2019-01-22

  Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

  本文描述了式 I′ 和 I 的化合物，它们可用作 sGC 的刺激剂，特别是 NO 依赖性、血红素依赖性刺激剂。这些化合物还可用于治疗、预防或控制本文公开的各种疾病。